{"url_path":"/sec/artv/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-213242-index.html","accession_number":"0001193125-26-213242","cik":"0001817241","ticker":"ARTV","issuer_name":"Artiva Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-213242-index.html","primary_entity_key":"0001817241","primary_entity_name":"Artiva Biotherapeutics, Inc."},"word_count":44,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nTrading Arrangements\n\nDuring the quarter ended March 31, 2026, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).\n\n \n\n \n\n93"}